Abstract

 The high mortality rate and the enormous socio-economic consequences of the COVID-19 virus epidemic require the immediate development of effective treatment methods. The main complication of coronavirus infection, leading to the development of a fatal outcome, is pneumonia, respiratory and multiple organ failure, which develop in some patients with COVID-19 infection. An analysis of the clinical, laboratory, and pathoanatomical picture of COVID-19 virus damage according to the literature suggests that there is a presence in the pathogenesis of patients with chronic disseminated intravascular coagulation (chronic DIC) and intraalveolar fibrinogenesis. Prevention of these processes, early therapy using the systemic method of leech therapy (SMP) of hirudotherapy, which has about 30 types of therapeutic effects, including anticoagulant and thrombolytic effects, can prevent the development of severe, lifethreatening complications.

Keywords: COVID-19; Microthromboses; Systemic Method of Leech Therapy (SMP); Hirudotherapy

References

1. ACC/Chinese Cardiovascular Association COVID-19 Webinar 1.
2. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet10223 (2020): 507-513.
3. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
4. Tang N., et al. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis (2020).
5. Wu C., et al. “Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China”. JAMA Internal Medicine (2020).
6. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet 20 (2020): 30566-30563.
7. Guidelines for the prevention and treatment of new coronary viral infection COVID-19. The First Academic Clinic of Zhejiang University School of Medicine. Edition. Tingbo Liang. Moscow (2020): 92.
8. Liu X., et al. “Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction”. Preprint med Rxiv.
9. Barkagan ZS. “Hemorrhagic diseases and syndromes”. M: Medicine (1988): 236.
10. Lane DA., et al. “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey”. Chest5 (2010): 1093-100.
11. Gromov A.A., et al. “Coronavirus COVID-19- unapplied treatment possible” (2020).
12. Krashenyuk AI., et al. “The role of the systemic method of girulotherapy in the treatment of the elderly. Non-drug medicine”. Scientific and Practical Journal 1 (2007): 59-73.
13. Baskova IP., et al. “Theory and practice”. M (2004): 507.
14. Barabas E., et al. “Hirudin”. Methods in Enzymology 45 (1976): 669-678.
15. Dodt J., et al. “The complete amino acid sequence of hirudin, a thrombin specific inhibitor”. FEBS Letters 165 (1984):180-183.
16. Dodt J., et al. “The complete amino acid sequence of hirudin. Localisation of disulfide bonds”. Biological Chemistry 366 (1985): 379-385.
17. Harvey RP., et al. “Cloning and expression of cDNA coding for the anticoagulant hirudin from the blood sucking leech, Hirudo medicinalis”. Proceedings of the National Academy of Sciences of the United States of America 83 (1986):1084-1088.
18. Matheson AJ and Goa KL. “Desirudin: a review of its use in the management thrombotic disorders”. Drugs 60 (2000): 679-700.
19. Markwardt F. “Hirudin as alternative anticoagulant – a historical review”. Seminars in Thrombosis and Hemostasis 5 (2002): 405-414.
20. Nikonov GI and Latril J. “Scientific principles of hirudotherapy. In the book: Hirudotherapy and hirudopharmacotherapy”. In the book: “Hirudotherapy and hirudopharmacotherapy (Edition. By Nikonov G.I.), 4 (2002): 28-38.
21. Krashenyuk AI and Frolov DI. “Interpretation of the nature of the energy-information effect of hirudotherapy based on an acoustic phenomenon. In the book: Science”. Information. Consciousness., St. Petersburg (2001): 89-90.
22. Topol E.J., et al. “Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial”. Circulation 4 (1994): 1557-1566.
23. Cannon CP., et al. “A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-tipe plasminogen activator and aspirin for acute myocardial infarction: results of Thrombosis in Myocardial Infarction (TIMI) 5 trial”. Journal of the American College of Cardiology 23 (1994): 993-1003.
24. Serruys PW., et al. “A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators”. New England Journal of Medicine 12 (1995): 757-763.
25. Eriksson BI., et al. “Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement”. Seminars in Thrombosis and Hemostasis 2 (1994): 227-231.
26. Eriksson BI., et al. “Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393”. Lancet 347 (1996): 635-639.
27. Kemkes-Matthes B. “Hirudin for prophylaxis and treatment of deep vein thrombosis”. Seminars in Thrombosis and Hemostasis 28 (2002): 455-458.
28. Nicolaides AN. “Clinical results with direct thrombin inhibitors”. Pathophysiology of Haemostasis and Thrombosis 3 (2002): 36-38.
29. Dulnev GN and Krashenyuk AI. “From Synergetics to Information Medicine”. St. Petersburg, Institute of Biosensory Psychology (2010): 167.
30. Krashenyuk AI. “Clinical Case of Conservative Leech Treatment of Neurinoma of the Brain”. Acta Scientific Medical Sciences1 (2020): 108-110.
31. Krashenyuk AI. “Nerotrophic (Neural Stimulating) and Neuromediator Effects of Hirudo medicinalis. Patrogenetic Mechanism of Treatment of Diseases of the Nervous System of the Human”. Acta Scientific Medical Sciences3 (2020): 01-06.
32. Krashenyuk AI., et al. “Wave effects of medical leeches. Bulletin of the "International medical leech center”. Hirudotherapy and hirudopharmacotherapy. Edition. Doctor of Biological Sciences Nikonova G.I 4 (2002): 79-96.
33. Vlaskin SV., et al. “Resonance wave therapy and diagnostics. Study results and Prospects for use in leech therapy. Second World Congress hirudotherapy”. Abstracts of Reports 7.8 (2016): 35-39.
34. Krashenyuk AI., et al. “Aqua-communication effect of ultraviolet irradiation and the phenomenon of the remote transmission of this effect from person to person”. In the book: “Science. Information. Consciousness". Abstracts XIV. International Congress on Bioelectrography. St. Petersburg, 3.4 (2010): 27.

Citation

Citation: Albert Ivanovich Krashenyuk. “Coronavirus COVID-19 - Theoretical and Practical Substantiations for Reducing Mortality from Complications". Acta Scientific Medical Sciences 4.6 (2020): 115-123.

Copyright

Copyright: © 2020 Albert Ivanovich Krashenyuk. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.